Comparison of oral fluconazole versus itraconazole for treatment of recurrent oral candidiasis
DOI:
https://doi.org/10.66344/jpad.31.2.2021.1744Abstract
Objective To compare the efficacy of oral fluconazole versus itraconazole in oral candidiasis.
Â
Methods This study was conducted at the Outpatient Department of Dermatology, DHQ Teaching Hospital, Sargodha Medical College Sargodha. A total of 240 patients were included in this study were divided into two groups containing 120 patients in each group. Both groups applied 2% miconazole gel orally thrice daily for 7-14 days. In addition, group A was prescribed fluconazole 50mg once daily and group B was prescribed itraconazole 100mg twice daily for 7-14 days. Each patient was followed up monthly either physically or on phone for 6 months.
Â
Results In group A, the total number of 45 patients (37.5%) reported back with oral candidiasis whereas 19 patients (15.83%) of group B reported back with oral candidiasis.
Â
Conclusion It is concluded that itraconazole is better than fluconazole for the treatment of recurrent oral candidiasis with a similar duration of treatment.
Â
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Zaib, Farwa Naqvi, Saira Mohsin, Nadeem Yaqoob, Abdul Mudabbir Rehan, Ahmad Amin Khan Fraz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
